Corcept Therapeutics Incorporated
CORT
Kedudukan dalam Saham
#1756
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Harga Saham
$112.72
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$12.18B
Perubahan (1 hari)
2.32%
Perubahan (1 tahun)
43.41%
Negara
US
Perdagangan Corcept Therapeutics Incorporated (CORT)
Kategori
Healthcare
Pendapatan untuk Corcept Therapeutics Incorporated (CORT)
Pendapatan pada Jun 2026 TTM: $26.37M
Menurut laporan kewangan terkini Corcept Therapeutics Incorporated, pendapatan semasa syarikat ialah $26.37M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $124.56M, peningkatan berbanding pendapatan pada tahun 2022 yang berjumlah $116.19M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Corcept Therapeutics Incorporated dari 2001 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $26.37M | -83.67% |
| 2024 | $161.49M | 29.65% |
| 2023 | $124.56M | 7.20% |
| 2022 | $116.19M | -7.05% |
| 2021 | $125.01M | -5.01% |
| 2020 | $131.60M | 12.79% |
| 2019 | $116.68M | 26.61% |
| 2018 | $92.15M | 74.51% |
| 2017 | $52.81M | 548.72% |
| 2016 | $8.14M | -227.03% |
| 2015 | $-6.41M | -79.58% |
| 2014 | $-31.38M | -31.79% |
| 2013 | $-46.01M | 20.93% |
| 2012 | $-38.05M | 17.60% |
| 2011 | $-32.35M | 24.60% |
| 2010 | $-25.97M | 28.76% |
| 2009 | $-20.17M | 0.52% |
| 2008 | $-20.06M | 73.34% |
| 2007 | $-11.57M | -53.47% |
| 2006 | $-24.87M | 23.79% |
| 2005 | $-20.09M | -99.87% |
| 2004 | $-15.53B | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $1.35B | 5,019.14% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $1.21B | 4,470.06% |
HK
|
